Cencora (COR) Q3 2026 earnings review
Margin Expansion and Buybacks Drive EPS Outperformance
Cencora delivered a robust Q3 26 with revenue up 5.1% to $84.8B and Adjusted EPS surging 12.0% to $4.48. While revenue growth is Decelerating from the high-single-digit rates of FY25, the company's profitability is Accelerating. The integration of high-margin MSO assets like OneOncology expanded Adjusted Gross Margin by 61 basis points to 4.16%. Management aggressively executed its planned $1B share repurchase program early, which, combined with the margin expansion, prompted a raise in FY26 Adjusted EPS guidance to $17.75-$17.95.
🐂 Bull Case
The OneOncology and Retina Consultants of America (RCA) acquisitions are structurally elevating Cencora's margin profile. U.S. Healthcare adjusted operating margin expanded to 1.29%, driving a 15.9% increase in segment operating income despite top-line headwinds.
Management completed its planned $1B share repurchase program by the end of Q3—months ahead of the calendar year-end target. This signals supreme confidence in near-term free cash flow generation and the debt-paydown trajectory.
🐻 Bear Case
The MSO acquisitions came at a steep cost. Adjusted operating expenses jumped 26.8% YoY, drastically outpacing revenue growth. Simultaneously, net interest expense skyrocketed 72% YoY to $140.7M due to acquisition-related debt.
The core U.S. segment faces ongoing revenue friction from IRA WAC reductions, faster-than-expected brand-to-biosimilar conversions, and the lapping of prior customer losses (oncology and grocery).
⚖️ Verdict: 🟢
Bullish. The strategic pivot toward higher-margin specialty services (MSOs) is paying off exactly as management planned. While debt and OpEx are higher, the resulting margin expansion and aggressive share repurchases easily support the raised EPS guidance.
Key Themes
MSO Platform Driving Profitability Upgrade
Cencora's pharmaceutical-centric strategy is Accelerating. The integration of OneOncology and RCA is fundamentally shifting the margin profile of the U.S. Healthcare segment. Despite only a 4.9% increase in segment revenue, U.S. Healthcare operating income surged 15.9% to $966.2M. The MSO business provides a high-growth, higher-margin revenue stream that creates pull-through for Cencora's broader specialty distribution network.
International Segment Turnaround
Reversing its previous sluggishness, the International Healthcare Solutions segment was a standout performer. Revenue grew 5.9% to $7.68B, and operating income jumped 20.8% to $165.9M. This was driven by a robust recovery in the European distribution business and the global specialty logistics unit (World Courier), which successfully lapped the clinical trial softness seen in FY25.
Accelerate Pharmacy Solutions & Digital Transformation
Management continues to emphasize digital transformation within the supply chain. The rollout of the 'Accelerate Pharmacy Solutions' portfolio for health systems is gaining traction, providing integrated software and workflow solutions that embed Cencora deeper into hospital operations and drive high-margin specialty pharmaceutical utilization.
Operating Expenses Outpacing Revenue
While the consolidated Adjusted Operating Income narrative is positive (+17.0%), it masks a structural bloat in expenses. Adjusted operating expenses surged 26.8% to $2.28B, vastly outpacing the 5.1% revenue growth. This indicates that Cencora's margin expansion is heavily reliant on gross profit keeping pace with a significantly higher fixed-cost structure post-OneOncology acquisition.
Interest Expense Drag from M&A
The debt taken on to fund the OneOncology transaction is heavily taxing the bottom line. Net interest expense for Q3 was $140.7M, a massive 72% increase compared to $81.8M in the prior year quarter. While management is paying down term loans, this structural headwind requires monitoring.
Macro Impact: IRA WAC Reductions
The macro policy environment remains a tangible headwind. Cencora cited manufacturer list price reductions linked to the Inflation Reduction Act (IRA) and faster-than-expected brand-to-biosimilar conversions in the mail-order channel as factors suppressing U.S. Healthcare revenue growth, which Decelerated to 4.9%.
GLP-1 Margin Dilution
Sales of GLP-1 products for diabetes and weight loss continue to drive immense volume through the network. However, these are fundamentally low-margin products for wholesale distributors. As GLP-1s become a larger mix of total revenue, they act as a persistent drag on consolidated gross margin percentages, placing the burden entirely on the MSO segment to drive margin accretion.
Other KPIs
Accelerating. Up 61 basis points from 3.55% a year ago. This is a massive expansion for a distributor, driven almost entirely by the integration of the OneOncology and RCA assets into the U.S. Healthcare Solutions segment.
Up 24.8% YoY on 6.9% revenue growth. This segment includes MWI Animal Health and Profarma. The outsized profit growth was materially aided by an accounting benefit: MWI's classification as an 'asset held for sale' suspended its depreciation expense for the quarter.
Operating cash flow was $1.69B, offset by $511M in capital expenditures. Cencora is in a heavy investment cycle (targeting a second national distribution center), but cash generation remains sufficient to support the recently completed $1B share repurchase program.
Guidance
Accelerating. Raised from the previous range of $17.70 - $17.90. The midpoint of $17.85 implies roughly 11.6% YoY growth versus FY25's $16.00. This raise is underpinned by the early completion of the $1B share repurchase program and strong operational execution in Q3.
Key Questions
U.S. Organic Growth ex-M&A
U.S. Healthcare operating income grew 15.9%, but adjusted operating expenses jumped 26.8% consolidated. Excluding the OneOncology acquisition, what was the true organic operating profit growth and expense leverage in the core distribution business this quarter?
MWI Divestiture Timing
The 'Other' segment benefited from MWI being held for sale, suspending depreciation. What is the updated timeline for the Covetrus merger close, and how will the lost operating income be replaced or offset in FY27?
GLP-1 Margin Trajectory
GLP-1 volumes remain strong. Are you seeing any early signs of manufacturers adjusting remuneration models or generic/oral alternatives that could shift the current 'minimally profitable' dynamic of this massive revenue stream?